nodes	percent_of_prediction	percent_of_DWPC	metapath
Tripelennamine—HRH1—Histamine receptors—HRH3—attention deficit hyperactivity disorder	0.151	0.183	CbGpPWpGaD
Tripelennamine—HRH1—Monoamine GPCRs—ADRA2C—attention deficit hyperactivity disorder	0.041	0.0498	CbGpPWpGaD
Tripelennamine—HRH1—Monoamine GPCRs—DRD5—attention deficit hyperactivity disorder	0.0402	0.0488	CbGpPWpGaD
Tripelennamine—HRH1—Amine ligand-binding receptors—ADRA2C—attention deficit hyperactivity disorder	0.0345	0.0419	CbGpPWpGaD
Tripelennamine—HRH1—Amine ligand-binding receptors—DRD5—attention deficit hyperactivity disorder	0.0338	0.041	CbGpPWpGaD
Tripelennamine—HRH1—Monoamine GPCRs—HTR1B—attention deficit hyperactivity disorder	0.0244	0.0296	CbGpPWpGaD
Tripelennamine—HRH1—Amine ligand-binding receptors—HRH3—attention deficit hyperactivity disorder	0.0234	0.0285	CbGpPWpGaD
Tripelennamine—HRH1—Monoamine GPCRs—DRD1—attention deficit hyperactivity disorder	0.0226	0.0275	CbGpPWpGaD
Tripelennamine—HRH1—Monoamine GPCRs—DRD3—attention deficit hyperactivity disorder	0.0219	0.0266	CbGpPWpGaD
Tripelennamine—HRH1—Monoamine GPCRs—ADRA2A—attention deficit hyperactivity disorder	0.0216	0.0262	CbGpPWpGaD
Tripelennamine—HRH1—Monoamine GPCRs—DRD4—attention deficit hyperactivity disorder	0.0213	0.0259	CbGpPWpGaD
Tripelennamine—HRH1—Amine ligand-binding receptors—HTR1B—attention deficit hyperactivity disorder	0.0205	0.0249	CbGpPWpGaD
Tripelennamine—HRH1—Monoamine GPCRs—DRD2—attention deficit hyperactivity disorder	0.0198	0.0241	CbGpPWpGaD
Tripelennamine—HRH1—Amine ligand-binding receptors—DRD1—attention deficit hyperactivity disorder	0.019	0.0231	CbGpPWpGaD
Tripelennamine—Pargyline—MAOA—attention deficit hyperactivity disorder	0.0189	0.107	CrCbGaD
Tripelennamine—HRH1—Amine ligand-binding receptors—DRD3—attention deficit hyperactivity disorder	0.0184	0.0224	CbGpPWpGaD
Tripelennamine—HRH1—Amine ligand-binding receptors—ADRA2A—attention deficit hyperactivity disorder	0.0181	0.022	CbGpPWpGaD
Tripelennamine—HRH1—Amine ligand-binding receptors—DRD4—attention deficit hyperactivity disorder	0.0179	0.0217	CbGpPWpGaD
Tripelennamine—Captodiame—DRD3—attention deficit hyperactivity disorder	0.0175	0.0991	CrCbGaD
Tripelennamine—HRH1—Amine ligand-binding receptors—DRD2—attention deficit hyperactivity disorder	0.0167	0.0202	CbGpPWpGaD
Tripelennamine—HRH1—Monoamine GPCRs—HTR2A—attention deficit hyperactivity disorder	0.0139	0.0169	CbGpPWpGaD
Tripelennamine—Phenoxybenzamine—ADRA2C—attention deficit hyperactivity disorder	0.0137	0.0773	CrCbGaD
Tripelennamine—Bepridil—CACNA1C—attention deficit hyperactivity disorder	0.0129	0.0729	CrCbGaD
Tripelennamine—HRH1—Amine ligand-binding receptors—HTR2A—attention deficit hyperactivity disorder	0.0117	0.0142	CbGpPWpGaD
Tripelennamine—CYP2D6—Melatonin metabolism and effects—MAOA—attention deficit hyperactivity disorder	0.0112	0.0136	CbGpPWpGaD
Tripelennamine—Doxepin—ADRA2C—attention deficit hyperactivity disorder	0.0111	0.0629	CrCbGaD
Tripelennamine—HRH1—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.00792	0.00962	CbGpPWpGaD
Tripelennamine—HRH1—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.00776	0.00942	CbGpPWpGaD
Tripelennamine—HRH1—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.0077	0.00936	CbGpPWpGaD
Tripelennamine—Chlorphenamine—SLC6A3—attention deficit hyperactivity disorder	0.00735	0.0416	CrCbGaD
Tripelennamine—HRH1—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.00678	0.00824	CbGpPWpGaD
Tripelennamine—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.00665	0.00807	CbGpPWpGaD
Tripelennamine—Benzphetamine—SLC6A3—attention deficit hyperactivity disorder	0.00622	0.0352	CrCbGaD
Tripelennamine—Benzphetamine—ADRA2A—attention deficit hyperactivity disorder	0.0061	0.0345	CrCbGaD
Tripelennamine—Cyclobenzaprine—HTR2A—attention deficit hyperactivity disorder	0.00604	0.0341	CrCbGaD
Tripelennamine—Phenoxybenzamine—ADRA2A—attention deficit hyperactivity disorder	0.00583	0.033	CrCbGaD
Tripelennamine—Chlorphenamine—SLC6A4—attention deficit hyperactivity disorder	0.00549	0.0311	CrCbGaD
Tripelennamine—HRH1—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.00538	0.00653	CbGpPWpGaD
Tripelennamine—Promazine—DRD4—attention deficit hyperactivity disorder	0.00536	0.0303	CrCbGaD
Tripelennamine—HRH1—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.00517	0.00628	CbGpPWpGaD
Tripelennamine—CYP2D6—Phase 1 - Functionalization of compounds—MAOA—attention deficit hyperactivity disorder	0.00509	0.00618	CbGpPWpGaD
Tripelennamine—HRH1—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.00506	0.00615	CbGpPWpGaD
Tripelennamine—HRH1—IL-4 Signaling Pathway—EP300—attention deficit hyperactivity disorder	0.00496	0.00603	CbGpPWpGaD
Tripelennamine—Doxepin—ADRA2A—attention deficit hyperactivity disorder	0.00474	0.0268	CrCbGaD
Tripelennamine—HRH1—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.0047	0.00571	CbGpPWpGaD
Tripelennamine—HRH1—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.00461	0.0056	CbGpPWpGaD
Tripelennamine—Promazine—DRD1—attention deficit hyperactivity disorder	0.00454	0.0257	CrCbGaD
Tripelennamine—HRH1—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.00437	0.00531	CbGpPWpGaD
Tripelennamine—HRH1—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.00435	0.00529	CbGpPWpGaD
Tripelennamine—HRH1—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00423	0.00514	CbGpPWpGaD
Tripelennamine—Promazine—ADRA2A—attention deficit hyperactivity disorder	0.00422	0.0238	CrCbGaD
Tripelennamine—HRH1—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.00416	0.00505	CbGpPWpGaD
Tripelennamine—Amitriptyline—HTR1B—attention deficit hyperactivity disorder	0.00414	0.0234	CrCbGaD
Tripelennamine—HRH1—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.00411	0.00499	CbGpPWpGaD
Tripelennamine—HRH1—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.00403	0.00489	CbGpPWpGaD
Tripelennamine—Amitriptyline—DRD3—attention deficit hyperactivity disorder	0.00402	0.0227	CrCbGaD
Tripelennamine—HRH1—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.00395	0.0048	CbGpPWpGaD
Tripelennamine—HRH1—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.00383	0.00465	CbGpPWpGaD
Tripelennamine—Imipramine—SLC6A3—attention deficit hyperactivity disorder	0.00376	0.0213	CrCbGaD
Tripelennamine—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.00374	0.00455	CbGpPWpGaD
Tripelennamine—Amitriptyline—ADRA2A—attention deficit hyperactivity disorder	0.00367	0.0207	CrCbGaD
Tripelennamine—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.00363	0.0044	CbGpPWpGaD
Tripelennamine—Doxepin—SLC6A4—attention deficit hyperactivity disorder	0.00362	0.0205	CrCbGaD
Tripelennamine—Doxepin—DRD2—attention deficit hyperactivity disorder	0.0036	0.0204	CrCbGaD
Tripelennamine—HRH1—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.00356	0.00433	CbGpPWpGaD
Tripelennamine—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00352	0.00428	CbGpPWpGaD
Tripelennamine—HRH1—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00351	0.00426	CbGpPWpGaD
Tripelennamine—HRH1—G alpha (q) signalling events—HTR2A—attention deficit hyperactivity disorder	0.00347	0.00421	CbGpPWpGaD
Tripelennamine—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.00328	0.00398	CbGpPWpGaD
Tripelennamine—Promazine—DRD2—attention deficit hyperactivity disorder	0.0032	0.0181	CrCbGaD
Tripelennamine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	0.0031	0.00377	CbGpPWpGaD
Tripelennamine—HRH1—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.00307	0.00372	CbGpPWpGaD
Tripelennamine—HRH1—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	0.00292	0.00355	CbGpPWpGaD
Tripelennamine—HRH1—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	0.00286	0.00347	CbGpPWpGaD
Tripelennamine—HRH1—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	0.00285	0.00346	CbGpPWpGaD
Tripelennamine—Imipramine—SLC6A4—attention deficit hyperactivity disorder	0.00282	0.0159	CrCbGaD
Tripelennamine—Imipramine—DRD2—attention deficit hyperactivity disorder	0.0028	0.0158	CrCbGaD
Tripelennamine—Amitriptyline—SLC6A4—attention deficit hyperactivity disorder	0.0028	0.0158	CrCbGaD
Tripelennamine—Amitriptyline—DRD2—attention deficit hyperactivity disorder	0.00278	0.0157	CrCbGaD
Tripelennamine—Doxepin—HTR2A—attention deficit hyperactivity disorder	0.00278	0.0157	CrCbGaD
Tripelennamine—HRH1—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	0.00276	0.00335	CbGpPWpGaD
Tripelennamine—CYP2D6—Biological oxidations—COMT—attention deficit hyperactivity disorder	0.00272	0.00331	CbGpPWpGaD
Tripelennamine—HRH1—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	0.00271	0.0033	CbGpPWpGaD
Tripelennamine—CYP2D6—Biological oxidations—MAOA—attention deficit hyperactivity disorder	0.0027	0.00328	CbGpPWpGaD
Tripelennamine—CYP2D6—Metapathway biotransformation—COMT—attention deficit hyperactivity disorder	0.00268	0.00326	CbGpPWpGaD
Tripelennamine—HRH1—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	0.00268	0.00326	CbGpPWpGaD
Tripelennamine—HRH1—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	0.00268	0.00326	CbGpPWpGaD
Tripelennamine—HRH1—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	0.00265	0.00322	CbGpPWpGaD
Tripelennamine—HRH1—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	0.0026	0.00316	CbGpPWpGaD
Tripelennamine—HRH1—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	0.0025	0.00303	CbGpPWpGaD
Tripelennamine—Promazine—HTR2A—attention deficit hyperactivity disorder	0.00247	0.014	CrCbGaD
Tripelennamine—HRH1—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	0.00233	0.00284	CbGpPWpGaD
Tripelennamine—HRH1—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	0.0023	0.00279	CbGpPWpGaD
Tripelennamine—Imipramine—HTR2A—attention deficit hyperactivity disorder	0.00216	0.0122	CrCbGaD
Tripelennamine—Amitriptyline—HTR2A—attention deficit hyperactivity disorder	0.00215	0.0122	CrCbGaD
Tripelennamine—HRH1—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	0.00198	0.00241	CbGpPWpGaD
Tripelennamine—HRH1—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	0.00182	0.00221	CbGpPWpGaD
Tripelennamine—HRH1—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	0.0018	0.00219	CbGpPWpGaD
Tripelennamine—HRH1—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	0.00175	0.00212	CbGpPWpGaD
Tripelennamine—HRH1—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	0.00173	0.0021	CbGpPWpGaD
Tripelennamine—HRH1—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	0.00161	0.00196	CbGpPWpGaD
Tripelennamine—HRH1—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	0.00157	0.00191	CbGpPWpGaD
Tripelennamine—HRH1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	0.00157	0.0019	CbGpPWpGaD
Tripelennamine—HRH1—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	0.00156	0.0019	CbGpPWpGaD
Tripelennamine—HRH1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	0.00153	0.00186	CbGpPWpGaD
Tripelennamine—HRH1—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	0.00153	0.00186	CbGpPWpGaD
Tripelennamine—HRH1—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	0.00151	0.00184	CbGpPWpGaD
Tripelennamine—HRH1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	0.0015	0.00183	CbGpPWpGaD
Tripelennamine—HRH1—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	0.00146	0.00178	CbGpPWpGaD
Tripelennamine—HRH1—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	0.00142	0.00172	CbGpPWpGaD
Tripelennamine—HRH1—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	0.00141	0.00171	CbGpPWpGaD
Tripelennamine—HRH1—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	0.00139	0.00169	CbGpPWpGaD
Tripelennamine—HRH1—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	0.00138	0.00167	CbGpPWpGaD
Tripelennamine—HRH1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	0.00128	0.00156	CbGpPWpGaD
Tripelennamine—CYP2D6—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.00111	0.00135	CbGpPWpGaD
Tripelennamine—HRH1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	0.00106	0.00129	CbGpPWpGaD
Tripelennamine—HRH1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	0.000988	0.0012	CbGpPWpGaD
Tripelennamine—HRH1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	0.00093	0.00113	CbGpPWpGaD
Tripelennamine—HRH1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	0.000897	0.00109	CbGpPWpGaD
Tripelennamine—HRH1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	0.000864	0.00105	CbGpPWpGaD
Tripelennamine—HRH1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	0.000837	0.00102	CbGpPWpGaD
Tripelennamine—HRH1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	0.000823	0.000999	CbGpPWpGaD
Tripelennamine—HRH1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	0.000813	0.000987	CbGpPWpGaD
Tripelennamine—CYP2D6—Metabolism—TPH2—attention deficit hyperactivity disorder	0.000768	0.000933	CbGpPWpGaD
Tripelennamine—CYP2D6—Metabolism—CACNB2—attention deficit hyperactivity disorder	0.000768	0.000933	CbGpPWpGaD
Tripelennamine—HRH1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	0.000757	0.000919	CbGpPWpGaD
Tripelennamine—CYP2D6—Metabolism—DPYD—attention deficit hyperactivity disorder	0.000756	0.000918	CbGpPWpGaD
Tripelennamine—CYP2D6—Metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000702	0.000853	CbGpPWpGaD
Tripelennamine—CYP2D6—Metabolism—SNAP25—attention deficit hyperactivity disorder	0.000614	0.000746	CbGpPWpGaD
Tripelennamine—CYP2D6—Metabolism—ADRA2A—attention deficit hyperactivity disorder	0.000585	0.00071	CbGpPWpGaD
Tripelennamine—HRH1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	0.00053	0.000644	CbGpPWpGaD
Tripelennamine—CYP2D6—Metabolism—COMT—attention deficit hyperactivity disorder	0.000465	0.000565	CbGpPWpGaD
Tripelennamine—CYP2D6—Metabolism—MAOA—attention deficit hyperactivity disorder	0.000462	0.000561	CbGpPWpGaD
Tripelennamine—HRH1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	0.000281	0.000341	CbGpPWpGaD
Tripelennamine—CYP2D6—Metabolism—EP300—attention deficit hyperactivity disorder	0.0002	0.000242	CbGpPWpGaD
